CL2014001619A1 - Antagonistas del receptor p75, seleccionados de compuestos tales como derivados de (heterociclilo tetrahidropiridina)-(piperazinil)-1-alcanolona y (heterociclilo dihidropiridina)-(piperazinil)-1-alcanona para el tratamiento y/o prevencion de vejiga sobrereactiva; y uso para el tratamiento y/o prevencion de vejiga sobrereactiva. - Google Patents

Antagonistas del receptor p75, seleccionados de compuestos tales como derivados de (heterociclilo tetrahidropiridina)-(piperazinil)-1-alcanolona y (heterociclilo dihidropiridina)-(piperazinil)-1-alcanona para el tratamiento y/o prevencion de vejiga sobrereactiva; y uso para el tratamiento y/o prevencion de vejiga sobrereactiva.

Info

Publication number
CL2014001619A1
CL2014001619A1 CL2014001619A CL2014001619A CL2014001619A1 CL 2014001619 A1 CL2014001619 A1 CL 2014001619A1 CL 2014001619 A CL2014001619 A CL 2014001619A CL 2014001619 A CL2014001619 A CL 2014001619A CL 2014001619 A1 CL2014001619 A1 CL 2014001619A1
Authority
CL
Chile
Prior art keywords
heterocyclyl
piperazinyl
prevention
treatment
overactive bladder
Prior art date
Application number
CL2014001619A
Other languages
English (en)
Inventor
Roberta Avallone
Marco Baroni
Tiziano Croci
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47429839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001619(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2014001619A1 publication Critical patent/CL2014001619A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014001619A 2011-12-20 2014-06-18 Antagonistas del receptor p75, seleccionados de compuestos tales como derivados de (heterociclilo tetrahidropiridina)-(piperazinil)-1-alcanolona y (heterociclilo dihidropiridina)-(piperazinil)-1-alcanona para el tratamiento y/o prevencion de vejiga sobrereactiva; y uso para el tratamiento y/o prevencion de vejiga sobrereactiva. CL2014001619A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11306709.4A EP2606894A1 (en) 2011-12-20 2011-12-20 Novel therapeutic use of p75 receptor antagonists

Publications (1)

Publication Number Publication Date
CL2014001619A1 true CL2014001619A1 (es) 2014-10-17

Family

ID=47429839

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001619A CL2014001619A1 (es) 2011-12-20 2014-06-18 Antagonistas del receptor p75, seleccionados de compuestos tales como derivados de (heterociclilo tetrahidropiridina)-(piperazinil)-1-alcanolona y (heterociclilo dihidropiridina)-(piperazinil)-1-alcanona para el tratamiento y/o prevencion de vejiga sobrereactiva; y uso para el tratamiento y/o prevencion de vejiga sobrereactiva.

Country Status (24)

Country Link
US (2) US20140296513A1 (es)
EP (2) EP2606894A1 (es)
JP (2) JP6275649B2 (es)
KR (1) KR20140103151A (es)
CN (1) CN104144688B (es)
AR (1) AR089344A1 (es)
AU (2) AU2012356922B2 (es)
BR (1) BR112014014933A2 (es)
CA (1) CA2859582A1 (es)
CL (1) CL2014001619A1 (es)
CO (1) CO6990740A2 (es)
CR (1) CR20140298A (es)
DO (1) DOP2014000137A (es)
EA (1) EA028616B1 (es)
HK (1) HK1198580A1 (es)
IL (1) IL233189A0 (es)
MA (1) MA35850B1 (es)
MX (1) MX2014007673A (es)
PE (1) PE20141854A1 (es)
PH (1) PH12014501390A1 (es)
SG (1) SG11201403390QA (es)
TN (1) TN2014000269A1 (es)
UY (1) UY34535A (es)
WO (1) WO2013092918A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2606894A1 (en) * 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
EP3634420A1 (en) 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
JP7530182B2 (ja) * 2020-02-06 2024-08-07 株式会社東芝 生体適合部材

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3236243A1 (de) 1982-09-30 1984-04-05 Merck Patent Gmbh, 6100 Darmstadt Schwefelhaltige indolderivate
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
AU728523C (en) 1996-10-21 2001-08-09 Nps Pharmaceuticals, Inc. Neurotrophin antagonist compositions
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
DE19826841A1 (de) 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU4198400A (en) 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862967B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
JP2008508358A (ja) 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
WO2007030939A2 (en) * 2005-09-15 2007-03-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
CN101284838B (zh) 2008-06-06 2011-05-04 天津药物研究院 含噻吩并吡啶的哌嗪类衍生物、其制备方法和用途
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
JP2010254641A (ja) * 2009-04-28 2010-11-11 Astellas Pharma Inc アゾールカルボキサミド化合物又はその塩
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) * 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists

Also Published As

Publication number Publication date
US20140296513A1 (en) 2014-10-02
EP2793889A1 (en) 2014-10-29
JP6275649B2 (ja) 2018-02-07
UY34535A (es) 2013-07-31
IL233189A0 (en) 2014-07-31
AR089344A1 (es) 2014-08-13
CN104144688A (zh) 2014-11-12
US9763940B2 (en) 2017-09-19
KR20140103151A (ko) 2014-08-25
EP2606894A1 (en) 2013-06-26
MA35850B1 (fr) 2014-12-01
SG11201403390QA (en) 2014-07-30
PH12014501390A1 (en) 2014-09-22
AU2017248550A1 (en) 2017-11-09
NZ626485A (en) 2016-11-25
CO6990740A2 (es) 2014-07-10
CR20140298A (es) 2014-10-29
HK1198580A1 (en) 2015-04-30
EA028616B1 (ru) 2017-12-29
CA2859582A1 (en) 2013-06-27
EA201491226A1 (ru) 2014-10-30
US20170056400A1 (en) 2017-03-02
JP2015500863A (ja) 2015-01-08
WO2013092918A1 (en) 2013-06-27
AU2012356922B2 (en) 2017-11-09
CN104144688B (zh) 2017-03-22
BR112014014933A2 (pt) 2017-06-13
DOP2014000137A (es) 2014-07-31
JP2018030865A (ja) 2018-03-01
MX2014007673A (es) 2014-11-14
AU2012356922A1 (en) 2014-07-17
TN2014000269A1 (en) 2015-09-30
PE20141854A1 (es) 2014-12-11

Similar Documents

Publication Publication Date Title
CL2014001280A1 (es) Compuestos derivados de 4-fenil -piridinas sustituidas, moduladores del receptor de nk1; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de la emesis, disfuncion vesical, depresion o ansiedad
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
CL2014001090A1 (es) Compuestos derivados de oxazolidinona biciclica; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis y dislipidemia.
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
BR112014010183A2 (pt) composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase
CL2015001483A1 (es) Compuestos derivados de hidroxiquinolina y otros heterociclos nitrogenados, antagonistas de los receptores muscarínicos y agonistas del receptor beta2 adrenérgico; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento o prevencion del asma, bronquitis cronica o epoc.
IL247854B (en) Muscarinic receptor antagonists, preparations containing them and their uses
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
LT3632919T (lt) Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
CL2016002498A1 (es) Compuestos de isoindolinona como modulares de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados.
DK3406609T3 (da) Bicykliske aza-forbindelser som muskariniske receptoragonister
CL2014000450A1 (es) Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros.
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
DK3183254T3 (da) Nye spiro[3h-indol-3,2 ?-pyrrolidin]-2(1h)-one forbindelser og derivater som mdm2-p53 inhibitorer
HUE058759T2 (hu) Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
LT2914255T (lt) Širdies ir kraujagyslių sistemos sutrikimų gydymas arba prevencija, skiriant kolchiciną
CL2008000119A1 (es) Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
CL2014000395A1 (es) Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor.
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
CL2013003686A1 (es) Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña.